The consensus price target for Chimerix, Inc. (NASDAQ: CMRX) has remained stable at $8.55, indicating analyst confidence in the company’s future.
Chimerix’s potential approval for dordaviprone could significantly impact its financial outlook, with projections of over $1 billion in U.S. revenue.
The Phase 3 ACTION study’s interim data readout in Q3 2025 is a critical event that could influence investor sentiment and price targets.
Chimerix, Inc. (NASDAQ: CMRX) is a biopharmaceutical company dedicated to developing treatments for serious diseases. Its portfolio includes TEMBEXA, a smallpox treatment, and several clinical-stage programs targeting tumors and cancers. The company is working on dordaviprone, a potential treatment for recurrent H3 K27M mutant high-grade glioma, with a PDUFA Priority Review date set for August 18, 2025.
The consensus price target for Chimerix has remained stable at $8.55 over the past year. This consistency suggests that analysts’ expectations for the company’s stock have not shifted significantly. Wedbush has also set a price target of $8.55, aligning with the consensus. This stability may reflect confidence in Chimerix’s ongoing projects and potential market opportunities.
Chimerix is on the brink of potentially securing the first approval for dordaviprone, which could significantly impact its financial outlook. The global market for brain tumor therapeutics is projected to reach $5.28 billion by 2030. Chimerix estimates it could generate over $1 billion in revenue from the U.S. alone, highlighting the potential financial impact of dordaviprone’s success.
The Phase 3 ACTION study is evaluating dordaviprone for front-line treatment of H3 K27M mutant high-grade glioma patients. An interim data readout on overall survival is expected in the third quarter of 2025. This data could influence analysts’ price targets and investor sentiment, as it will provide insights into the drug’s effectiveness and market potential.
Investors should monitor developments in Chimerix’s clinical trials and broader market trends in the biopharmaceutical sector. Staying informed about these factors can help in making more informed investment decisions regarding Chimerix, Inc. News on clinical trials, partnerships, and financial earnings reports can provide valuable insights into the company’s future prospects.
